TBPH vs ZYME
TBPH: A commercial-stage biopharmaceutical company with an FDA-approved COPD inhalation therapy under review for strategic alternatives following a failed neurology pipeline program. ZYME: A clinical-stage biotechnology firm building value through a portfolio of novel multifunctional biotherapeutics and strategic royalty assets.
Side-by-side fundamentals
| Metric | TBPH | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $17.01 | $28.67 | |
| Market cap as of 2026-08-24 | $883M | $2.0B | |
| P/E as of 2026-08-24 | 7.72 | n/a | |
| PEG as of 2026-08-24 | 0.05 | n/a | |
| Net margin as of 2026-08-24 | +104.3% | -126.3% | TBPH higher |
| Gross margin as of 2026-08-24 | +100.0% | n/a | |
| Operating margin as of 2026-08-24 | +46.8% | -140.3% | TBPH higher |
| ROE as of 2026-08-24 | +43.9% | -37.8% | TBPH higher |
| ROA as of 2026-08-24 | +25.5% | -25.2% | TBPH higher |
| Debt / equity as of 2026-08-24 | 0.11 | 1.51 | TBPH lower |
| Revenue growth (YoY) as of 2026-08-24 | +68.2% | +3.3% | TBPH higher |
| Revenue CAGR (3y) SEC XBRL | +27.9% | -36.4% | TBPH higher |
| Beta as of 2026-08-24 | 0.59 | 1.15 | |
| 1-year return as of 2026-08-24 close | +22.3% | +99.2% | ZYME higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.